Physician profile
Eric D Hilmes
NPI 1902050388
$14,792.58
in general payments reported to CMS, 2019-2025
30 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,310 · 2022: $4,578 · 2023: $2,731 · 2024: $2,534 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,921 · Consulting Fee: $625 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,920.97 |
| Consulting Fee | $625.00 |
| Education | $358.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,783.09 | 2021-2025 | |
| Ucb, INC. | $1,443.15 | 2021-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $1,191.80 | 2023-2025 | Zoryve |
| Epi Health, LLC | $895.12 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $764.46 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $694.87 | 2021-2025 | Tremfya |
| Genzyme Corporation | $676.77 | 2021-2024 | |
| Strata Skin Sciences, INC. | $610.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $594.67 | 2021-2025 | |
| Journey Medical Corporation | $568.90 | 2021-2025 | |
| Incyte Corporation | $456.20 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $413.47 | 2023-2024 | Vtama |
| Pfizer INC. | $373.82 | 2021-2025 | |
| Leo Pharma INC. | $355.33 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $321.66 | 2021-2023 | Enbrel, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $292.41 | 2022 | |
| Galderma Laboratories, L.P. | $262.02 | 2021-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.62 | 2023 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $219.24 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $178.58 | 2021-2024 | Taltz, Ebglyss, Zepbound |
| Revance Therapeutics, INC. | $99.05 | 2024 | Daxxify |
| Vyne Pharmaceuticals INC. | $58.28 | 2021 | |
| Boston Scientific Corporation | $46.11 | 2022-2024 | |
| Dermira, INC. | $43.79 | 2021 | |
| Biofrontera INC. | $43.43 | 2022-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $41.36 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.78 | 2021-2025 | Siliq, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $26.09 | 2025 | Sotyktu |
| Merz North America, INC. | $25.53 | 2023 | Xeomin |
| Kaleo, INC. | $18.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Hilmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.